Company Overview and News

2
Main Street Capital's Detailed Dividend Sustainability Analysis (Includes First Half Of 2019 Special Periodic Dividend Projection)

2018-10-15 seekingalpha
Following continued requests, this article analyzes MAIN’s dividend sustainability by performing three tests based on recent historical and projected future quarterly results.
AIY AINV FSIC MAIN MCQ AIB MCV OSLE PSEC OCSL MSCA.CL MCX SLRC MSCA TWO PBB SLRA MCC

30
Why I Sold This 11.1% Yielding BDC That Could Now Be A 'Buy'

2018-10-11 seekingalpha - 5
FSIC was my smallest position and I sold before the recent declines for the reasons discussed in this article.
CCT AIY AINV CLA SDRPQ MCQ HRZN HTF KAP BKCC MCV BBDC OSLE MM ACTPF KCAP ABDC HTFA TSG CPTA FDMCF AST MCC GSBD HDSN TCRX GARS HCAPL MMCC FSIC TCPC AIB TCRD TCRZ PSEC SD TSLF OCSI SDOCQ OCSL MCX HCAP SDRXP PBB SDRXQ

8
This Stable 10.1% Yielding BDC Is A Strong Buy At These Levels

2018-10-04 seekingalpha
TCPC is a higher quality BDC and is currently trading lower (below book value) for the reasons discussed in this article.
AIY AINV GAIN HTF KAP BKCC PFLT BBDC OSLE KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD PSEC NMFC TSLF MCX HCAP PBB CLA MCQ GAINM HRZN PNNT MCV GADDP CGBD HTGZ MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC PNTA

2
Mispriced Baby Bond, Bargain With A 7.6% Yield To Maturity

2018-09-29 seekingalpha - 1
Medley Management is in the process of merging with two of the business development companies that it manages to form a large internally managed BDC.
MCX AIY AINV CLA MDLX MDLY MCQ CPTA AIB MCV MCC

 
MCX / Medley Capital Corporation 8-K (Current Report)

2018-09-28 sec.gov
Document UNITED STATES
MCX

5
Prospect Capital's Detailed Dividend And NAV Sustainability Analysis - Part 2 (Includes Remaining Fiscal Year 2019 Monthly Dividend Projection)

2018-09-27 seekingalpha
Part 2 of this article discusses two topics/trends impacting PSEC’s future dividend and NAV sustainability (forward-looking metrics).
AIY AINV GAIN MCQ GAINM MCV PFLT OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK TRI NEWTL PBB

8
Potentially Oversold Best Of Breed BDC: Initiating Coverage

2018-09-19 seekingalpha
Earlier this year, I initiated active coverage of GAIN (8.2% yield) and its preferred stocks GAINM (6.2% yield) and now its newly issued GAINL (6.3% yield).
AIY AINV CLA GAIN GAINM MCQ KAP PNNT BKCC MCV PFLT OSLE GADDP GAINL GLADO HTGZ KCAP GLAD ABDC MSCA CPTA MCC TCRX ARCC HCAPL FSIC MAIN TCPC AIB TCRD TCRZ PSEC HTGX NMFC HTGY TSLF OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PBB PNTA

8
Approaching Oversold Conditions, Driving 9% Yield With Upcoming Specials

2018-09-13 seekingalpha - 1
I recently purchased additional shares of this higher quality BDC that's trading 6% below book value paying a 9% dividend yield with an upcoming special dividend in Q4.
AIY AINV CLA MCQ KAP PNNT BKCC MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC CPTA MCC TCRX ARCC HCAPL FSIC TCPC AIB TCRD TCRZ PSEC HTGX NMFC TSLF HTGY OCSI ARU OCSL MCX HCAP SUNS HTGC PBB PNTA

6
Main Street Capital's NAV, Dividend, And Valuation Compared To 14 BDC Peers (Post Q2 2018 Earnings) - Part 2

2018-09-13 seekingalpha
Part 2 of this article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK MDLY NEWTL PBB

4
Prospect Capital's NAV, Valuation, And Dividend Compared To 14 BDC Peers (Post Q2 2018 Earnings)

2018-09-10 seekingalpha
Following multiple requests, this “supplemental” article compares PSEC’s recent quarterly change in NAV, quarterly and trailing twelve-month economic return, NII, and current valuation to 14 BDC peers.
AIY AINV GAIN MCQ GAINM MCV PFLT OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC MAIN TCPC AIB PSEC NEWTZ ARU OCSL MSCA.CL MCX BLK NEWTL PBB

5
High-Yield BDC Sector Return And Expense Ratios

2018-09-04 seekingalpha
This article compares the return and expense ratios for the BDC sector so that investors can identify which companies are efficiently able to distribute higher returns to shareholders.
CLA MCQ MRCC MCV PFLT OSLE HTGZ ABDC MSCA TSLX CPTA MCC GSBD TCRX GBDC MAIN TCRD TCRZ PSEC HTGX TSLF HTGY OCSI OCSL MSCA.CL MCX SUNS HTGC PBB

7
Oil-Exposed BDCs Continue To Rally But Still Yield 9% To 11%

2018-08-29 seekingalpha
Most BDCs with higher exposure to oil-related investments have rebounded over the last two quarters partially due to rising oil prices and LIBOR resulting in higher book values and earnings.
AIY AINV GAIN HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD NMFC TSLF MCX HCAP CLA MCQ GAINM HRZN PNNT MCV GADDP CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC PNTA

5
Assessing Oaktree Strategic Income's Results For Fiscal Q3 2018 (Includes Current Recommendation)

2018-08-27 seekingalpha
Due to the recent change in management, readers have asked if I could take a look at OCSI to determine whether operations have improved enough to currently justify an investment.
ACSF AIY AINV GAIN MCQ GAINM OAK MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX BLK NEWTL PBB

7
9.3% Yield And Recent Rally From Rising Book Value

2018-08-22 seekingalpha
PNNT has rallied 15% since my previous article predicting that the company would report increased book value/NAV per share due to rebounding oil prices and accretive share repurchases.
AIY AINV HTF KAP BKCC PFLT BBDC OSLE GLADO KCAP ABDC HTFA TSLX HCAPL FSIC FDUS MAIN AIB TCRD PSEC NMFC TSLF MCX HCAP PBB CLA MCQ HRZN PNNT MCV CGBD HTGZ GLAD MSCA CPTA MCC TCRX ARCC GARS GBDC TCPC TCRZ HTGX HTGY OCSI ARU OCSL MSCA.CL SUNS HTGC PNTA

5
Analyzing Oaktree Specialty Lending's Results For Fiscal Q3 2018 (Includes Investment Rating Analysis)

2018-08-20 seekingalpha
This article assesses OCSL’s performance for the fiscal third quarter of 2018 (calendar second quarter of 2018) and compares results over the trailing twelve months.
ACSF AIY AINV GAIN MCQ GAINM OAK MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MO MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX BLK NEWTL PBB

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to MCX / Medley Capital Corporation on message board site Silicon Investor.

Datamirror (DMCX) (T.DMC) Datamirror (DMCX) (T.DMC) Datamirror (DMCX) (T.DMC) AMCX - AMERICLEAN, INC. AMCX - AMERICLEAN, INC. AMCX - AMERICLEAN, INC.
SMCX - RUN-UP HAS BEGUN - SOLID COMPANY JUST DISCOVERED... SMCX - RUN-UP HAS BEGUN - SOLID COMPANY JUST DISCOVERED... SMCX - RUN-UP HAS BEGUN - SOLID COMPANY JUST DISCOVERED... ImageMatrix (IMCX) Savior of the HMOu0027s? ImageMatrix (IMCX) Savior of the HMOu0027s? ImageMatrix (IMCX) Savior of the HMOu0027s?
CUSIP: 58503F906